Neil Morganstein, MD

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Neil Morganstein, MD, discusses the mechanism of action of lurbinectedin in metastatic small cell lung cancer.